Cargando…

Differential drug response in pulmonary arterial hypertension: The potential for precision medicine

Pulmonary arterial hypertension (PAH) is a rare, complex, and deadly cardiopulmonary disease. It is characterized by changes in endothelial cell function and smooth muscle cell proliferation in the pulmonary arteries, causing persistent vasoconstriction, resulting in right heart hypertrophy and fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Elise, Sampson, Chinwuwanuju Ugo‐Obi, Desai, Ankit A., Karnes, Jason H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621006/ https://www.ncbi.nlm.nih.gov/pubmed/37927610 http://dx.doi.org/10.1002/pul2.12304

Ejemplares similares

Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension
por: Fazal, Shahood, et al.
Publicado: (2021)

Diagnostic and therapeutic algorithm for pulmonary arterial hypertension
por: Desai, Ankit A., et al.
Publicado: (2011)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Unveiling the Genetic Architecture of Human Disease for Precision Medicine
por: Ramamoorthy, Anuradha, et al.
Publicado: (2018)

Survival in pulmonary arterial hypertension: A brief review of registry data
por: Pauwaa, Sunil, et al.
Publicado: (2011)

Pulmonary Arterial Hypertension in Genetic and Comorbid Settings: A Step Forward for Precision Medicine
por: Madonna, Rosalinda
Publicado: (2022)

Multiparameter use of Cardiac Magnetic Resonance as a predictor of pulmonary artery hypertension
por: Avery, Ryan, et al.
Publicado: (2016)

Precision medicine: The future of diagnostic approach to pulmonary hypertension?
por: Kedzierski, Piotr, et al.
Publicado: (2019)

Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1–7)-Mas Axis in Pulmonary Arterial Hypertension
por: Zhang, Feng, et al.
Publicado: (2021)

Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension
por: Manzi, Giovanna, et al.
Publicado: (2021)

Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice
por: Kelly, Neil J., et al.
Publicado: (2022)

Cytokine profiling in pulmonary arterial hypertension: the role of redox homeostasis and sex
por: RAFIKOV, RUSLAN, et al.
Publicado: (2022)

Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines
por: Ramamoorthy, Anuradha, et al.
Publicado: (2019)

Targeting BMPR2 Trafficking with Chaperones: An Important Step toward Precision Medicine in Pulmonary Arterial Hypertension
por: Andruska, Adam, et al.
Publicado: (2020)

Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension
por: Sun, Yanan, et al.
Publicado: (2021)

New cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension
por: Kurdyukov, Sergey, et al.
Publicado: (2018)

From Big Data to Precision Medicine
por: Hulsen, Tim, et al.
Publicado: (2019)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension
por: Redel-Traub, Gabriel, et al.
Publicado: (2022)

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
por: Savale, Laurent, et al.
Publicado: (2018)

RASA3 is a candidate gene in sickle cell disease‐associated pulmonary hypertension and pulmonary arterial hypertension
por: Prohaska, Clare C., et al.
Publicado: (2023)

Inhibiting Jak2 Ameliorates Pulmonary Hypertension: Fulfilling the Promise of Precision Medicine
por: Leopold, Jane A.
Publicado: (2021)

New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023)

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension
por: Wu, Sheryl, et al.
Publicado: (2022)

Precision Medicines’ Impact on Orphan Drug Designation
por: Mueller, Christine M., et al.
Publicado: (2019)

Drug repositioning in pulmonary arterial hypertension: challenges and opportunities
por: Grinnan, Daniel, et al.
Publicado: (2019)

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension
por: Weatherald, Jason, et al.
Publicado: (2023)

Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension
por: Yu, Zhijie, et al.
Publicado: (2022)

Exertional dyspnoea in pulmonary arterial hypertension
por: Dumitrescu, Daniel, et al.
Publicado: (2017)

Machine learning to differentiate pulmonary hypertension due to left heart disease from pulmonary arterial hypertension
por: Swinnen, Katleen, et al.
Publicado: (2023)

The isobaric pulmonary arterial compliance in pulmonary hypertension
por: Chemla, Denis, et al.
Publicado: (2021)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Hypoxia-induced pulmonary hypertension in type 2 diabetic mice
por: Pan, Minglin, et al.
Publicado: (2017)

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude
por: Dubroff, Jason, et al.
Publicado: (2020)

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
por: Norell, Puck N., et al.
Publicado: (2022)

Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension
por: Xue, Zhifeng, et al.
Publicado: (2021)

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
por: Alencar, Allan K. N., et al.
Publicado: (2017)

Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2017)

Network module‐based drug repositioning for pulmonary arterial hypertension
por: Wang, Rui‐Sheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rm5eq8d2eqf3umoh71rtpdigv8